Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, provides an overview of CO-1686.

Over the past 10 years, oncologists have been able to use first-generation EGFR inhibitors to treat patients with EGFR-positive lung cancer. However, patients will eventually develop acquired resistance to these agents through a second mutation in EGFR known as 

Allen says Clovis has developed CO-1686 to inhibit T790M as well as the activating mutations in EGFR while sparing the inhibition of the normal, or wild-type, EGFR. 

Data for CO-1686 were first presented at ASCO in 2013 with a follow-up this year. Prior to the 2014 ASCO Annual Meeting, CO-1686 was granted a breakthrough therapy designation from the FDA. 

Allen says data on CO-1686 presented at the 2014 ASCO Annual meeting showed that patients with confirmed 

 mutations saw a 60% objective response rate when treated with CO-1686 alone. The median progression-free survival has not yet been reached, Allen says, but the current estimate exceeds 12 months. 

Andrew R. Allen, BM, BCh, MA, MRCP, PhD

Articles

Dr. Allen Discusses CO-1686 as a Treatment for Lung Cancer